SCHEMBL435366

SCHEMBL435366

O=c1cc(C=Cc2ccccc2)oc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 1.00
KDM4E B2RXH2 5/20 1.00
MAPT P10636 4/20 1.00
ALDH1A1 P00352 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
NPC1 O15118 2/20 1.00
RAB9A P51151 2/20 1.00
NPSR1 Q6W5P4 1/20 1.00
HTT P42858 1/20 0.64
GRM4 Q14833 1/20 0.61
STS P08842 1/20 0.60
ADORA3 P0DMS8 4/20 0.51
TP53 P04637 2/20 0.51
CYP3A4 P08684 2/20 0.51
GABRP O00591 1/20 0.51
GABRD O14764 1/20 0.51
CA12 O43570 1/20 0.51
TNKS O95271 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465240 1.00 HPGD (1.00) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9975965 0.88 KDM4E (0.78) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9976005 0.88 KDM4E (0.78) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL10615084 0.88 KDM4E (0.78) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9976007 0.88 KDM4E (0.78) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL28245558 0.85 KDM4E (0.74) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9975966 0.84 KDM4E (0.72) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9976004 0.84 KDM4E (0.72) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9976009 0.84 KDM4E (0.72) HPGDKDM4EMAPTALDH1A1SMN1; SMN2
SCHEMBL9975962 0.84 MAPT (0.80) HPGDKDM4EMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104593443-A Preparation method of agilawood chromone component GUANGDONG INST MICROBIOLOGY 2015-05-06 CN claimed
CN-101525323-B Novel styryl chromone type compound and preparation method and use thereof CHUNHUA YANG 2011-06-15 CN claimed
CN-101525323-A Novel styryl chromone type compound and preparation method and use thereof CHUNHUA YANG 2009-09-09 CN claimed
JP-4225973-A None JP disclosed
WO-2020193802-A1 POLYMERIC CONJUGATES AND USES THEREOF FUNDACIÓN DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE (ES) 2020-10-01 WO disclosed
US-20190192473-A1 Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea AmDerma Pharmaceuticals, LLC 2019-06-27 US disclosed
US-20190192474-A1 Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer AmDerma Pharmaceuticals, LLC 2019-06-27 US disclosed
US-10278941-B2 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma AmDerma Pharmaceuticals, LLC (US) 2019-05-07 US disclosed
US-10278940-B2 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer AmDerma Pharmaceuticals, LLC (US) 2019-05-07 US disclosed
US-20180028484-A1 Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea AmDerma Pharmaceuticals, LLC 2018-02-01 US disclosed
US-20170231932-A1 METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS AmDerma Pharmaceuticals, LLC 2017-08-17 US disclosed
WO-2005023183-A2 NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-03-17 WO disclosed
US-20050059655-A1 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use NITROMED, INC. (US) 2005-03-17 US disclosed
WO-2005018561-A2 NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-03-03 WO disclosed
US-5409952-A Anticancer agents ADIR ET COMPAGNIE (FR) 1995-04-25 US disclosed
US-5409952-A Anticancer agents ADIR ET COMPAGNIE (FR) 1995-04-25 US disclosed
JP-H04225973-A NOVEL HETEROCYCLIC COMPOUND, 2-STYRYL-4H-1-BENZOPYRAN-4-ONE, ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT ADIR 1992-08-14 JP disclosed
EP-0454587-A1 Heterocyclic derivatives: 2-styryl-4H-1-benzopyran-4-ons, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1991-10-30 EP disclosed
EP-0454587-A1 Heterocyclic derivatives: 2-styryl-4H-1-benzopyran-4-ons, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1991-10-30 EP disclosed
US-RE28698-E Electrophotographic material containing sensitizers MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JA) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190192473-A1 Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea CYP8B1, CYP1B1, CYP26B1 HPGD 198/4885KDM4E 2246/4885MAPT 2619/4885
US-10278940-B2 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer CYP8B1, CYP26B1, CYP24A1 HPGD 219/4885KDM4E 540/4885MAPT 3634/4885
US-20170231932-A1 METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS IL2, IL2RA, IL5 HPGD 2149/4885KDM4E 1383/4885MAPT 2045/4885
US-20190192474-A1 Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer CYP8B1, CYP26B1, CYP24A1 HPGD 219/4885KDM4E 540/4885MAPT 3634/4885
US-20050059655-A1 Nitrosated and nitrosylated diuretic compounds, compositions and methods of use REN, NOS1, NOS3 HPGD 60/4885KDM4E 3048/4885MAPT 3126/4885
US-20180028484-A1 Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Rosacea CYP8B1, CYP1B1, CYP26B1 HPGD 198/4885KDM4E 2246/4885MAPT 2619/4885
US-10278941-B2 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of glioma ALDH1A2, IDH3A, IDH3B HPGD 179/4885KDM4E 1649/4885MAPT 1843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.